Perbedaan Kadar LDH Serum Total Sebelum dan Sesudah Kemoterapi pada Berbagai Kelompok Stadium Kanker LNH

Hamidah Hamidah; Muh.Darwin Prenggono; Farida Heriyani

doi:10.20527/jbk.v12i1.356

Perbedaan Kadar LDH Serum Total Sebelum dan Sesudah Kemoterapi pada Berbagai Kelompok Stadium Kanker LNH

Hamidah Hamidah, Muh.Darwin Prenggono, Farida Heriyani

Abstract

Abstract: Lactate dehydrogenase (LDH) is tumor prognostic for Non Hodgkin Lymphoma (NHL) and it levels would be elevated. The several papers has reported there are an association of total serum LDH levels and staging group of NHL. The study aimed to determine the differences of total serum LDH levels before and after the combination chemotherapy CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) for NHL’s patients at RSUD Ulin Banjarmasin during 3 years. It was an observational analyticstudy design and cross-sectional approach, data collected with design method of totally sampling. Of the 51 patient medical records who included, 54,9% were staging group I-II and 45,1% were staging group III-IV. The first statistic analytic used dependent T test with p=0,303 (p>0,05)showed no differencesof total serum LDH levels before and after the combination chemotherapy CHOP in NHL’s patients with staging group I-II. The second statistic analytic used alternative wilcoxon test with p=0,013 (p<0,05) showed differencesof total serum LDH levels before and after the combination chemotherapy CHOP in NHL’s patients with staging groupIII-IV. The third statistic analytic used alternative mann whitney test with p=0,161 (p>0,05) showed no differencesof total serum LDH levels after the combination chemotherapy CHOP in NHL’s patients between staging group I-II and III-IV.

Keywords: total serum LDH levels, NHL, combination chemotherapy CHOP

Abstrak: Laktat dehidrogenase (LDH) adalah tumor prognostic pada kanker Limfoma Non Hodgkin (LNH) dan kadarnya selalu menunjukan peningkatan. Penelitian sebelumnya melaporkan bahwa terdapat hubungan antara kadar LDH serum total dengan kelompok stadium kanker LNH. Penelitian ini bertujuan untuk mengetahui perbedaan kadar LDH serum total sebelum dan sesudah kemoterapi kombinasi CHOP (Siklofosfamid, Doksorubisin, Vinkristin, dan Prednison) pada penderita kanker LNH di RSUD Ulin Banjarmasin selama 3 tahun.Penelitian ini menggunakan rancangan studi observasional analitik dan metode pendekatan cross sectional, pengambilan sampel dengan teknik rancangan totally sampling. Dari 51 data rekam medik yang termasuk kriteria inklusi, 54,9% kelompok stadium I-II dan 45,1% kelompok stadium III-IV. Analisis statistik pertama menggunakan uji T berpasangandengan p=0,303 (p>0,05) sehingga tidak terdapat perbedaan kadar LDH serum total sebelum dan sesudah kemoterapi kombinasi CHOP pada penderita kanker LNH kelompok stadium I-II. Analisis statistik kedua menggunakan uji alternatif yaitu uji wilcoxondengan p=0,013 (p<0,05) sehingga terdapat perbedaan kadar LDH serum total sebelum dan sesudah kemoterapi kombinasi CHOP pada penderita kanker LNH kelompok stadium III-IV. Analisis statistik ketiga menggunakan uji alternatif yaitu uji mann whitney dengan p=0,161 (p>0,05) sehingga tidak terdapat perbedaan kadar LDH serum total sesudah kemoterapi kombinasi CHOP pada penderita kanker LNH antara kelompok stadium I-II dan III-IV.

Kata-kata kunci: kadar LDH serum total, LNH, kemoterapi kombinasi CHOP

Full Text:

PDF

References

Reksodiputro AH, Irawan C. Limfoma maligna non Hodgkin. Dalam: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku ajar ilmu penyakit dalam. Jilid II. Edisi 5. Jakarta Pusat: Internal Publishing Pusat Penerbitan Ilmu Penyakit Dalam Diponegoro 71; 2009.

Bakta IM. Hematologi klinik ringkas. Cetakan I. Jakarta: EGC; 2007.

Casulo C, Rich L. Non Hodgkin lymphoma. United States: Leukemia and Lymphoma Society; 2013.

Anonim. Cancer fact and figure. Atlanta: American Cancer Sosiety; 2009.

Boffetta P. Epidemiology of adult non Hodgkin lymphoma. Annals of Oncology. 2011;22(4):27-31.

Reksodiputro AH, Irawan C, Hardjolukito E, et al. Non Hodgkin lymphoma in Jakarta. Indonesian Journal of Cancer. 2011;5(3):129-133.

Armitage OJ. Staging non Hodgkin lymphoma. CA Cancer Journal for Clinicians. 2005;55:368-376.

Mulyono A, Ugroseno, Sedana MP, dkk. Asosiasi CA 125 dengan respon terapi pada penderita limfoma non Hodgkin agresif yang mendapat kemoterapi cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). J Peny Dalam. 2011;12(3):200-208.

Kasir DR, Wahid I, Bachtiar H. Hubungan kadar laktat dehidrogenase dengan stadium limfoma non Hodgkin di rumah sakit Dr. M. Djamil Padang periode Desember 2009 sampai Maret 2013. Jurnal Kesehatan Andalas. 2014;3(2):128-130.

Ugroseno, Ali M, Boediwarsono. Lactate dehydrogenase level and the response of non Hodgkin lymphoma patients to chemoterapy cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Folia Medica Indonesiana. 2008;44(3):184-187.

Murray RK, Granner DK, Rodwell VW. Biokimia harper. Edisi 27. Jakarta: EGC; 2006.

Heiden M, Cantley L, Thompson C. Understanding the Warburg Effect: the metabolic requirement of cell proliferation. Science Journal. 2009;324:1029-1033.

Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E.Energy metabolism in tumor cells.FEBS J.2007;274:1393-1418.

Nam SO, Yotsumoto F, Miyata K, Shirasu N, Miyamoto S and Kuroki M.Possible therapeutic targets among the molecules involved in the Warburg effect in tumor cells.Anticancer Research.2013;33:2855-2860.

Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica Oncology Journal. 2008;93:9-13.

Opyrchal M, Figanbaum T, Ghosh A, Vincent R, Caples S. Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma. 2010;ID 610969:1-3.

Lupu Anca, Radu Paul, Pana Bogdan, Kalfas Cristina. R-CHOP vs. CHOP: a cost effectiveness analysis on aggressive non Hodgkin’s lymphoma (NHL). Management in Health. 2009;13(2):119-129.

Lindh J, Lenner P, Osterman B, Roos G. Prognostic significant of serum lactic dehydrogenase levels and fraction of S-phase cells in non-Hodgkin Lymphomas. Eur J Haematol. 1993;50:258-63.

Murakami J, Shimizu Y.Hepatic manifestation in haematological disorders; Review Article. International Journal of Hepatology. 2013;ID484903:1-13.

Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence based review. Journal of Clinical Oncology. 2008;26(16):2767-2778.

Casciato DA. Manual of clinical oncology. 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2004.

Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffused histiocytic lymphoma; the Southwest Oncology Group Experience. J Clin Oncol. 1986;4:295-305.

DOI: http://dx.doi.org/10.20527/jbk.v12i1.356